Tumour-targeted nanomedicines: principles and practice

Lammers, Twan; Hennink, Wim E.; Storm, Gerrit

doi:10.1038/sj.bjc.6604483

Cited by 490 publications

(360 citation statements)

References 30 publications

Supporting

Mentioning

355

Contrasting

Unclassified

Order By: Relevance

“…In 1971, Judah Folkman suggested that the tumor growth might be inhibited by preventing tumors from recruiting new blood vessels (Folkman, 1971;Danhier et al, 2010). This observation is the base of the design of nanomedicines actively targeted to tumor endothelial cells (Lammers et al, 2008, Danhier et al, 2010. By attacking the growth of the blood supply, the size and metastatic capabilities of tumors can be controlled.…”

Section: Targeting Of Tumoral Endotheliummentioning

confidence: 99%

“…However, the primary consideration as designing any drug delivery system is to control the drug concentration in the therapeutic window, while plummeting side effects and improving patient compliance. This allows useful treatment cycles to be maintained, and at the same time decreases damage to healthy cells and diminishes the recovery period (Peer et al, 2007;Davis, 2008;Lammers et al, 2008;Dinarvand et al, 2011). Poly (lactic-coglycolic acid) (PLGA) is one of the most successfully used biodegradable polymers because its hydrolysis leads to metabolite monomers, lactic acid and glycolic acid.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

PLGA-Based Nanoparticles as Cancer Drug Delivery Systems

Mirakabad

Nejati-Koshki²,

Akbarzadeh³

et al. 2014

Asian Pacific Journal of Cancer Prevention

375

150

View full text Add to dashboard Cite

Section: Targeting Of Tumoral Endotheliummentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

PLGA-Based Nanoparticles as Cancer Drug Delivery Systems

Mirakabad

Nejati-Koshki²,

Akbarzadeh³

et al. 2014

Asian Pacific Journal of Cancer Prevention

375

150

View full text Add to dashboard Cite

“…administration. Based on this notion, and on the fact that drug targeting systems are known to be able to improve both the temporal (circulation time, tumour residence time) and the spatial (tumour accumulation, tumour-to-organ ratio) parameters of drug therapy (Moses et al, 2003;Torchilin, 2005;Duncan, 2006;Lammers et al, 2008), we reasoned that the implementation of a drug targeting system might be able to increase the therapeutic index of radiochemotherapy. The rationale for this novel combination regimen, which we have termed 'carrier-based radiochemotherapy', relies on the notion that on the one hand, radiotherapy improves drug targeting (i.e.…”

mentioning

confidence: 99%

“…Drug targeting systems are generally designed to be stable in circulation, and to release the conjugated or entrapped active agent only at the target site (Torchilin, 2005;Duncan, 2006;Lammers et al, 2008). As a result, as compared to an i.v.…”

mentioning

confidence: 99%

Image-guided and passively tumour-targeted polymeric nanomedicines for radiochemotherapy

Subr²,

et al. 2008

Self Cite

View full text Add to dashboard Cite

Drug targeting systems are nanometer-sized carrier materials designed for improving the biodistribution of systemically applied (chemo-) therapeutics. Reasoning that (I) the temporal and spatial interaction between systemically applied chemotherapy and clinically relevant fractionated radiotherapy is suboptimal, and that (II) drug targeting systems are able to improve the temporal and spatial parameters of this interaction, we have here set out to evaluate the potential of 'carrier-based radiochemotherapy'. N-(2-hydroxypropyl)methacrylamide (HPMA) copolymers were used as a model drug targeting system, doxorubicin and gemcitabine as model drugs, and the syngeneic and radio-and chemoresistant Dunning AT1 rat prostate carcinoma as a model tumour model. Using magnetic resonance imaging and g-scintigraphy, the polymeric drug carriers were first shown to circulate for prolonged periods of time, to localise to tumours both effectively and selectively, and to improve the tumour-directed delivery of low molecular weight agents. Subsequently, they were then shown to interact synergistically with radiotherapy, with radiotherapy increasing the tumour accumulation of the copolymers, and with the copolymers increasing the therapeutic index of radiochemotherapy (both for doxorubicin and for gemcitabine). Based on these findings, and on the fact that its principles are likely broadly applicable, we propose carrier-based radiochemotherapy as a novel concept for treating advanced solid malignancies.

show abstract

“…[38,215] Although the EPR effect is attested to be a universal phenomenon for all type of solid cancer tumors, the EPR-assisted tumor accumulation of nanomedicines has been demonstrated only in limited type of cancers. [38] However, the EPR phenomenon is implausible to be present, if not equally present in all types of tumors.…”

Section: Epr In Humansmentioning

confidence: 99%

Bridging the Knowledge of Different Worlds to Understand the Big Picture of Cancer Nanomedicines

Balasubramanian

Liu

Hirvonen

et al. 2017

Adv Healthcare Materials

View full text Add to dashboard Cite

Explosive growth of nanomedicines continues to significantly impact the therapeutic strategies for effective cancer treatment. Despite the significant progress in the development of advanced nanomedicines, successful clinical translation remains challenging. As cancer nanomedicine is a multidisciplinary field, the fundamental problem is that the knowledge gaps stem from different vantage points in the understanding of cancer nanomedicines. The complexities and heterogenecity of both nanomedicines and cancer are further demanding the integration of highly diverse expertise to develop clinically translatable cancer nanomedicines. This progress report aims to discuss the current understanding of cancer nanomedicines between different research areas in terms of nanoparticle engineering, formulation, tumor patho-physiology and clinical medicine, as well as to identify the knowledge gaps lying at the interface between the different fields of research in nanomedicine. Here we also highlight for the necessity to harmonize the multidisciplinary effort in the research of nanomedicines in order to bridge the knowledge and to advance the full understanding in cancer nanomedicines. A paradigm shift is needed in the strategic development of disease specific nanomedicines in order to foster the successful translation into clinic of future cancer nanomedicines.

show abstract

Tumour-targeted nanomedicines: principles and practice

Cited by 490 publications

References 30 publications

PLGA-Based Nanoparticles as Cancer Drug Delivery Systems

PLGA-Based Nanoparticles as Cancer Drug Delivery Systems

Image-guided and passively tumour-targeted polymeric nanomedicines for radiochemotherapy

Bridging the Knowledge of Different Worlds to Understand the Big Picture of Cancer Nanomedicines

Contact Info

Product

Resources

About